Adding the MF59® Adjuvant to the influenza vaccine significantly enhances antibody responses*1,2.
Antigen + MF59® Adjuvant
Increases the magnitude of the immune response by stimulating more immune cells to create more antibodies.*
Broadens the immune response by creating higher levels of cross-reactive antibodies.*
Impact of MF59® Adjuvant in Fluad.
Magnitude
Significantly higher antibody levels against homologous A/H1N1, A/H3N2 and B strains (p<0.001).*3
Breadth
Significantly higher antibody responses against selected heterologous A/H3N2 strains.*3-5
Persistence
Significantly longer antibody responses against the homologous A/H3N2 strain*†3
† Secondary endpoint. Primary endpoint was not met.
Haemagglutination inhibition (HI) antibody titres are used as a surrogate marker for protection against influenza.1
This may be important when circulating strains have drifted from vaccine strains.4
The duration of immunity varies for influenza vaccines, but it is usually 6–12 months.1
*compared to non-adjuvanted, standard dose influenza vaccines
Reference: 1. Seqirus NZ. FLUAD Data Sheet. Seqirus (NZ) Ltd. January 2020. 2. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59®-adjuvanted vaccine. Vaccine. 2001;19(17-19):2673-2680. 3. Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-5034. 4. O’Hagan DT, Rappuoli R, De Gregorio E, et al. MF59® adjuvant: the best insurance against infl uenza strain diversity. Expert Rev Vacc 2011; 10(4):447–462. 5. Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating infl uenza virus strains elicited by MF59®- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28(25):4123-4129.